

Korea Pharmaceutical Market & Approval system

Korea Pharmaceutical Traders Association Pharmaceutical Export Dept. Director

Ohhyun kwon




Korea Pharmaceutical Market

(Unit: ₩ 100 million)

Years	Production	Export	Import	Market Size	Import Share	Market Growth Rate
2010	157,098	17,810	54,184	193,472	28.0	6.18
2011	155,968	19,585	55,263	191,646	28.8	-0.94
2012	157,140	23,409	58,535	192,266	30.4	0.32
2013	163,761	23,306	52,789	193,244	27.3	0.51
2014	164,194	25,442	54,952	193,704	28.4	0.24

Source: MFDS, KPTA







- New Drug(ND), New Molecular Entity(NME)
- An active ingredient never marketed in Korea
- Incrementally Modified Drugs (IMD)
 - ✓ New derivative
- ✓ New efficacy
- ✓ New formulation

- ✓ New combination
- √ New intended use
- ✓ New route of Administration

Generic Drugs



> NDA



Safety and Efficacy Evaluation

- > Generic
 - Bioequivalence study
 - GMP documents
 - Chemistry, Manufacturing, Controls



- ✓ DMF (scope of drug substances to register)
- 1) Active drug substances of new drug
- 2) Drug substances designated (206 drug substances and their salts and hydrates)
- 3) Drug substances derived from human placenta
- ✓ Following data should be included in conformity with Regulation
- 1) Data on facility for manufacture and quality management
- 2) Data on physicochemical properties and stability
- 3) Data on manufacturing process, packaging, container, cautions in storage and handling, etc.
- 4) Data proving the eligibility of the substance (equivalent to KGMP or above the level of KGMP)
- 5) Data including batch analysis, analytical procedures, used solvent of drug substance
- 6) Sample drug substance for test
 - * Data can be submitted using the Common Technical Document



Thank You